WASHINGTON (Reuters) – The leaders of major insulin makers and pharmacy benefit managers (PBMs) are set to blame each other on Wednesday in their testimonies during a U.S. Senate committee hearing on making the life-saving drug more affordable. PBMs negotiate with drugmakers for rebates and lower fees on behalf of…Read More
Pharma CEOs to testify in US Senate hearing on insulin prices
